PRESS RELEASE published on 09/03/2024 at 10:15, 1 year 6 months ago Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL Press release regarding the declaration of the number of shares and voting rights at Sartorius Stedim Biotech S.A. in France Voting Rights Déclaration Shares Sartorius Stedim Biotech France
PRESS RELEASE published on 09/03/2024 at 10:15, 1 year 6 months ago Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL Sartorius Stedim Biotech SA declares the number of shares and voting rights in the issued capital. Total shares: 97,330,405. Total voting rights: 165,568,221 Voting Rights Shares Sartorius Stedim Biotech Issued Capital Announcement
BRIEF published on 08/02/2024 at 12:27, 1 year 7 months ago Sartorius Stedim Biotech Announces Share and Voting Rights Update Voting Rights Shares Regulatory Compliance Sartorius Stedim Biotech Issued Capital
PRESS RELEASE published on 08/02/2024 at 12:23, 1 year 7 months ago Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL Sartorius Stedim Biotech SA declares the total number of shares and voting rights, as of July 31, 2024, in compliance with legal requirements Voting Rights Déclaration Shares Sartorius Stedim Biotech SA July 31 2024
PRESS RELEASE published on 08/02/2024 at 12:22, 1 year 7 months ago Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL Sartorius Stedim Biotech SA declares the number of shares and voting rights in their issued capital. Details in the announcement Voting Rights Shares AMF Sartorius Stedim Biotech SA French Regulatory News
BRIEF published on 07/19/2024 at 09:55, 1 year 8 months ago Sartorius Stedim Biotech SA: Provision of financial documents Financial Results Investors Sartorius Stedim Biotech First Half Of 2024 Documents Available
PRESS RELEASE published on 07/19/2024 at 09:51, 1 year 8 months ago Sartorius Stedim Biotech SA: Information on Document Availability Sartorius Stedim Biotech Group releases first-half 2024 results report with business development and financial statements. Leading biopharmaceutical partner based in Aubagne, France Financial Statements Biopharmaceutical Industry Sartorius Stedim Biotech Group First-half 2024 Results Aubagne
PRESS RELEASE published on 07/19/2024 at 09:50, 1 year 8 months ago Sartorius Stedim Biotech SA: Information on Document Availability Sartorius Stedim Biotech SA releases information on the availability of documents, including first half 2024 results and financial statements Financial Results Investor Relations Sartorius Stedim Biotech Biopharmaceutical Industry Document Availability
PRESS RELEASE published on 07/19/2024 at 09:37, 1 year 8 months ago Half yearly financial reports and audit reports/limited reviews
PRESS RELEASE published on 07/18/2024 at 18:30, 1 year 8 months ago Half-year results 2024 of SartoriusStedimBiotech Sartorius Stedim Biotech reports half-year results for 2024 with sales revenue of 1,373 million euros and a cautious outlook for the year ahead due to market volatility Volatility Sartorius Stedim Biotech Sales Revenue Outlook Half-year Results
Published on 03/23/2026 at 22:40, 1 hour 19 minutes ago Troubadour Announces Withdrawal of Non-Brokered Private Placements
Published on 03/23/2026 at 22:30, 1 hour 29 minutes ago Gregory J. Leia Sells Shares in Waskahigan Oil & Gas Corp
Published on 03/23/2026 at 22:00, 1 hour 59 minutes ago Hillcrest Participates in APEC 2026 and Announces Shares for Debt Offering
Published on 03/23/2026 at 21:18, 2 hours 41 minutes ago Amdocs Announces Appointment of Shimie Hortig to the Board of Directors Upon Shuky Sheffer's Retirement as Director and Chief Executive Officer
Published on 03/23/2026 at 14:05, 9 hours 54 minutes ago Wellgistics Health Inc. Signs $105,000,000 Letter of Intent to Evaluate Potential Acquisition of Neuritek Therapeutics, Inc. which is Pioneering Innovative Therapies for Neurological and Psychiatric Disorders
Published on 03/23/2026 at 22:05, 1 hour 54 minutes ago DeFi Technologies Provides Update on Timing of Annual Filings
Published on 03/23/2026 at 21:05, 2 hours 54 minutes ago Abivax Announces Full Year 2025 Financial Results and Provides Business Updates
Published on 03/23/2026 at 21:00, 2 hours 59 minutes ago Persistent Appoints Ruchi Kulhari as Executive Vice President - Enterprise Strategy & Execution
Published on 03/23/2026 at 20:55, 3 hours 4 minutes ago Ordering Both ESR and CRP Lab Tests Could Save Hospitals Millions Per Year -- New Study Challenges Notion the Tests are Interchangeable
Published on 03/23/2026 at 19:08, 4 hours 51 minutes ago Reporting on share buyback transactions carried out between March 16 and March 20, 2026
Published on 03/23/2026 at 17:45, 6 hours 14 minutes ago ENGIE will build, own and operate its largest onshore wind farm worldwide in Egypt
Published on 03/23/2026 at 17:45, 6 hours 14 minutes ago Share buyback for allocation to employees or corporate officers
Published on 03/23/2026 at 17:35, 6 hours 24 minutes ago Disclosure of transactions in own shares from March 16 to March 20, 2026
